这可能是遗传性血管? - - 不同医学专业的观点
Markus Magerl1,2, Anna Sala-Cunill3, Christina Weber-Chrysochoou4
1Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Clinical and translational allergy
|September 25, 2023
概括
遗传性血管 (HAE) 是一种罕见的疾病,导致衰弱症状和诊断延迟. 提高跨专业意识对于及时诊断和改善HAE患者的生活质量至关重要.
科学领域:
- 遗传学和免疫学 遗传学和免疫学
- 罕见疾病 罕见疾病
- 患者的生活质量.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的自体主导性疾病.
- 患者在诊断中经历了显著的延迟,影响了生活质量.
- 症状包括严重的腹痛和胀,喉 edem 构成死亡风险.
研究的目的:
- 突出强调需要跨专业对HAE的认识.
- 为医疗保健专业人员,遇到HAE患者概述基本信息.
- 强调早期诊断的重要性,以改善患者的治疗结果.
主要方法:
- 审查来自不同医学专业的病例.
- 对HAE的诊断挑战和延迟的分析.
- 确定各种医疗保健专业人员的关键信息.
主要成果:
- 由于缺乏意识和症状与其他疾病重叠,诊断延迟很常见.
- 患者经常得到错误的诊断,并接受不必要的手术.
- 及时诊断和特定于HAE的治疗显著提高了生活质量.
结论:
- 跨专业教育对于早期HAE诊断至关重要.
- 跨专业的医疗保健专业人员必须了解HAE症状.
- 及时诊断和治疗对于管理HAE和改善患者生活质量至关重要.
相关概念视频
Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24
Aneurysm III: Interprofessional Care
9
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
9
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454


